Spirogen Overview
- Year Founded
-
2000
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$440M
- Investors
-
1
Spirogen General Information
Description
Operator of a clinical-stage biotechnology company intended to develop Deoxyribonucleic acid for minor groove binding molecules for the therapeutic treatment of cancers. The company specializes in The company developing a C2 unsaturated pyrrolobenzodiazepines dimer and a pyrrolobenzodiazepines dimer that is activated by hydrolysis and an achiral analog of duocarmycin that binds the A T rich deoxyribonucleic acid minor groove, thereby enabling clients to bind and cross-link specific sites of DNA of the cancer cell without distorting its DNA helix.
Contact Information
Website
www.spirogen.comCorporate Office
- The QMB Innovation centre
- 42 New Road, London Borough of Tower Hamlets
- London E1 2AX
- England, United Kingdom
Corporate Office
- The QMB Innovation centre
- 42 New Road, London Borough of Tower Hamlets
- London E1 2AX
- England, United Kingdom
Spirogen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 15-Oct-2013 | $440M | Completed | Clinical Trials - Phase 2 | ||
| 4. Later Stage VC | 14-Oct-2009 | Completed | Clinical Trials - Phase 2 | |||
| 3. Early Stage VC | 01-May-2003 | Completed | Product Development | |||
| 2. Early Stage VC | 01-Mar-2001 | $1.45M | $1.45M | Completed | Product Development | |
| 1. University Spin-Out | 01-Jan-2000 | Completed | Startup |
Spirogen Patents
Spirogen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210113587-A1 | Pyrrolobenzodiazepine-antibody conjugates | Inactive | 25-Nov-2014 | ||
| US-10188746-B2 | Pyrrolobenzodiazepines and conjugates thereof | Inactive | 10-Sep-2014 | ||
| US-20170340752-A1 | Pyrrolobenzodiazepines and conjugates thereof | Active | 10-Sep-2014 | ||
| JP-2017516766-A | Pyrrolobenzodiazepine compounds for the treatment of lymphoma | Pending | 30-May-2014 | ||
| AU-2015265638-A1 | Pyrrolobenzodiazepine compounds for treating lymphoma | Inactive | 30-May-2014 | C07D519/00 |
Spirogen Former Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Auven Therapeutics | PE/Buyout | Minority | ||
| Bloomsbury Bioseed Fund | Venture Capital | Minority | ||
| Bloomsbury Investment Capital | Corporation | Minority | ||
| Cambridge Research BioVentures | Venture Capital | Minority | ||
| Cambridge Research and Innovation | Venture Capital | Minority |
Spirogen FAQs
-
When was Spirogen founded?
Spirogen was founded in 2000.
-
Where is Spirogen headquartered?
Spirogen is headquartered in London, United Kingdom.
-
What industry is Spirogen in?
Spirogen’s primary industry is Drug Discovery.
-
Is Spirogen a private or public company?
Spirogen is a Private company.
-
What is the current valuation of Spirogen?
The current valuation of Spirogen is .
-
What is Spirogen’s current revenue?
The current revenue for Spirogen is .
-
How much funding has Spirogen raised over time?
Spirogen has raised $16.5M.
-
Who are Spirogen’s investors?
Auven Therapeutics, Bloomsbury Bioseed Fund, Bloomsbury Investment Capital, Cambridge Research BioVentures, and Cambridge Research and Innovation are 5 of 11 investors who have invested in Spirogen.
-
When was Spirogen acquired?
Spirogen was acquired on 15-Oct-2013.
-
Who acquired Spirogen?
Spirogen was acquired by MedImmune and AstraZeneca.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process